ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

NCT06824363 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor, Adult
Malignant Solid Tumor
Stomach Adenocarcinoma
Esophageal Adenocarcinoma

Interventions

DRUG: Tremelimumab
DRUG: Durvalumab

Sponsor

University of California, Irvine